Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7814232 | 0.84 | L3MBTL1 (0.53) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL30356302 | 0.84 | L3MBTL1 (0.53) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL5447861 | 0.78 | ALDH1A1 (0.68) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL29838620 | 0.78 | ALDH1A1 (0.68) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL11166274 | 0.78 | L3MBTL1 (0.47) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL14369899 | 0.77 | L3MBTL1 (0.48) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL18550739 | 0.77 | L3MBTL1 (0.48) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL27547230 | 0.76 | MAPT (0.44) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL6676214 | 0.76 | MAPT (0.44) | MAPTL3MBTL1ALDH1A1GAAKMT2A | |
| SCHEMBL18550663 | 0.75 | ALDH1A1 (0.61) | MAPTL3MBTL1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| CN-1119148-C | Use of 'alpha' 1L agonists in treatment of incontinence | BOEHRINGER INGELHEIM KG (DE) | 2003-08-27 | — | — | CN | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | MAPT 2876/4885L3MBTL1 3507/4885ALDH1A1 181/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | MAPT 2124/4885L3MBTL1 3906/4885ALDH1A1 28/4885 |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | COL1A1, TPSAB1, TACR1 | MAPT 875/4885L3MBTL1 1080/4885ALDH1A1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.